中药汤剂联合沙库巴曲缬沙坦治疗慢性心力衰竭疗效及安全性的Meta分析

目的:系统评价中药汤剂联合沙库巴曲缬沙坦(LCZ696)治疗慢性心力衰竭(CHF)的有效性和安全性。方法:检索PubMed、the Cochrane Library、EMbase、中国学术期刊全文数据库、万方数据库、维普数据库和中国生物医学文献数据库中关于中药汤剂联合LCZ696治疗CHF的随机对照试验,检索时限为建库至2022年9月1日。采用Cochrane偏倚风险评估工具对纳入文献进行质量评价,应用Rev Man 5.3软件进行Meta分析。结果:共纳入14项研究,涉及1 121例病人。Meta分析显示：与常规治疗基础上加用LCZ696比较,中药汤剂联合LCZ696治疗CHF的有效率更高[RR=1.23,95%CI(1.15,1.31),P<0.000 01],治疗后6 min步行距离[MD=46.41,95%CI(29.57,63.25),P<0.000 01]及左室射血分数[MD=5.07,95%CI(3.14,7.01),P<0.000 01]明显增加,治疗后左心室舒张末期内径[MD=-2.76,95%CI(-3.96,-1.55),P<0.000 0...     

松龄血脉康胶囊治疗高脂血症的系统评价

目的系统评价松龄血脉康胶囊治疗高脂血症的疗效和安全性。方法通过计算机检索中国知网、中国生物医学文献数据库、万方、维普等中文数据库,并检索Cochrane、PubMed、MedLine、EmBase等外文数据库,纳入相关随机对照试验(RCT)进行评价,采用RevMan5.3软件分析数据。结果纳入17篇RCTs,共1 488例病人。相较于西药组,松龄血脉康胶囊联合阿托伐他汀钙治疗的血脂总疗效高于对照组[相对危险度(RR)=1.26,95%置信区间(95%CI)1.07～1.49,P=0.006)];相较于西药组,松龄血脉康胶囊血脂总疗效改善率更高[RR=1.36,95%CI(1.12,1.65),P=0.002],能有效升高高密度脂蛋白胆固醇(HDL-C)水平[加权均方差(WMD)=0.13,95%CI(0.06,0.21),P=0.000 3],松龄血脉康胶囊联合西药能有效降低总胆固醇(TC)水平[WMD=-0.75,95%CI(-1.16,-0.34),P=0.000 3]、三酰甘油(TG)水平[WMD=-0.50,95%CI (-0.83,-0.16),P=0.004]、低密度脂蛋白胆固醇(LDL-C)水平[WMD=-0.47,95%CI(-0.86,-0.08),P=0.02];相较于西药组,应用松龄血脉康胶囊联合氟伐他汀钠胶囊、阿托伐他汀钙治疗后HDL-C水平高于对照组[WMD=0.41,95%CI(0.01,0.81),P=0.04][WMD=0.40,95%CI(0.34,0.46),P=0.000 001];相较于中成药组,松龄血脉康胶囊治疗后TC水平低于复方丹参片组[WMD=-0.92,95%CI (-1.26,-0.58),P=0.000 01],治疗后HDL-C水平高于复方丹参片组[WMD=0.42,95%CI(0.22,0.62),P=0.000 1]。结论松龄血脉康胶囊对TC、TG、LDL-C改善更有效,其余指标与其他中成药及西药近似,安全性指标与其他药物相比未见明显差异。     

滋补肝肾类方联合西药治疗帕金森病临床疗效的Meta分析

目的评价滋补肝肾类方联合西药治疗帕金森病的临床疗效和安全性。方法计算机检索中国期刊全文数据库(CNKI)、维普数据库(VIP)、万方数据库、中国生物医学数据库(CBM),筛选采用滋补肝肾类方联合西药治疗帕金森病的随机对照试验(RCTs)相关文献,汇总各研究的临床疗效数据,并使用RevMan 5.3软件进行Meta分析。结果最终纳入31篇文献,共涉及2 320例病人。Meta分析结果显示:滋补肝肾类方联合西药能明显提高帕金森病治疗的总有效率[OR=3.54,95%CI(2.56,4.88),P0.000 01];改善统一帕金森病评分量表(UPDRS、UPDRSⅠ～Ⅳ)评分[WMD=-8.31,95%CI(-9.88,-6.73),P0.000 01;WMD=-0.55,95%CI(-0.86,-0.24),P=0.000 5;WMD=-2.74,95%CI(-4.43,-1.06),P=0.001;WMD=-3.00,95%CI(-4.40,-1.61),P0.000 1;WMD=-1.42,95%CI(-2.67,-0.18),P=0.02];改善中医证候评分[WMD=-9.50,95%CI(-12.02,-6.98),P0.000 01];改善韦氏综合评定量表(Webster)评分[WMD=-3.22,95%CI(-4.16,-2.27),P0.000 01];减少不良反应的发生[OR=0.27,95%CI(0.16,0.48),P0.000 01]。结论滋补肝肾类方联合西药治疗帕金森病对比单纯西药治疗有更好的临床疗效。     

参松养心胶囊治疗阵发性房颤疗效和安全性的Meta分析

目的评价参松养心胶囊治疗阵发性心房颤动(PAF)的疗性和安全性。方法计算机检索中国学术期刊全文数据库(CNKI)、万方数据库(WANGFANG)、Pubmed数据库自建库至2015年,所有参松养心胶囊治疗阵发性心房颤动的试验,按照纳入标准与排除标准纳入参松养心胶囊治疗阵发性心房颤动的随机对照试验(RCTs)。由两名评价员独立评价文献质量、提取资料后交叉核对,最后采用Rev Man 5.3软件进行Meta分析。结果总共纳入17个研究文献,全部为中文文献,合计1 459例心衰病人,Jadad评分1分17篇,均为中文文献。利用Meta分析后得出:参松养心胶囊联合西药治疗相比较西药常规治疗能提高整体疗效[RR=4.06,95%CI(2.59,6.37),P0.000 01);可减少房颤发作次数[WMD=-2.70,95%CI(-3.10,-2.31)],P0.000 01)];增加病人左室射血分数[WMD=5.09,95%CI(4.46,5.72),P0.00001];缩小病人左房内径[LAD,WMD=-2.90,95%CI(-3.39,-2.41),P0.000 01];增加病人6分钟步行距离[WMD=48.96,95%CI(40.86,57.05),P0.000 01];提高病人生活质量(QOL)评估指数,改善生活质量[WMD=27.14,95%CI(25.23,29.06),P0.000 01]。结论参松养心胶囊组与单纯西药组比较治疗阵发性房颤可进一步提高临床疗效,对心功能的改善有一定的作用。但由于纳入文章整体质量、篇幅限制,所取样本量较小,仍需要更多高质量大规模的RCT进一步验证。     

泰脂安治疗高脂血症的系统评价

目的系统评价泰脂安治疗高脂血症的疗效和安全性。方法计算机检索Cochrane图书馆、PubMed、EMbase、中国知网(CNKI)、中国生物医学文献数据库(CBM)、维普中文期刊服务平台(VIP)、万方数据库等数据库,纳入相关随机对照试验(RCTs),并进行评价,采用RevMan5.3软件分析数据。检索时限从建库至2018年4月20日。结果最终纳入6篇RCTs,共631例受试者。相比对照组,泰脂安试验组的血脂总疗效高于对照组[RR=1.13, 95%CI(1.05, 1.22),P=0.001]。治疗后总胆固醇(TC)水平与对照组效果接近[WMD=-0.33, 95%CI(-0.84, 0.19),P=0.21],对于合并阴虚证的病人,治疗后TC水平低于对照组[WMD=0.03, 95%CI(0.22,0.28),P=0.82]。治疗后三酰甘油(TG)水平与对照组效果接近[WMD=-0.03, 95%CI(-0.23, 0.16),P=0.72]。治疗后高密度脂蛋白胆固醇(HDL-C)水平与对照组效果接近[WMD=0.15, 95%CI(-0.06, 0.36),P=0.15],对于合并阴虚证的病人,泰脂安治疗后HDL-C水平高于对照组[WMD=0.12, 95%CI(0.04, 0.20),P=0.004]。治疗后低密度脂蛋白胆固醇(LDL-C)水平与对照组效果接近[WMD=-0.12, 95%CI(-0.44, 0.20),P=0.47],对于合并阴虚证的病人,泰脂安治疗后LDL-C水平低于对照组[WMD=-0.57, 95%CI(-0.79,-0.34),P0.000 01]。各组不良反应发生率差异均无统计学意义[RR=0.15, 95%CI(0.01, 3.60),P=0.24]。结论现有证据表明泰脂安治疗高脂血症疗效较好,对TC、TG、HDL-C、LDL-C的改善有效,在高脂血症兼阴虚证的病人中,对TC、HDL-C、LDL-C改善较明显,不良反应发生率未见与其他药物有明显差异。     

替格瑞洛联合PCI治疗急性ST段抬高型心肌梗死有效性和安全性的Meta分析

目的系统评价替格瑞洛联合经皮冠状动脉介入(PCI)治疗急性ST段抬高型心肌梗死(STEMI)的有效性和安全性。方法通过计算机检索PubMed、万方、维普、中国学术期刊全文数据库。全面检索公开发表的替格瑞洛和氯吡格雷联合PCI治疗STEMI病人的随机对照研究,检索时间设置为建库至2018年8月。从中筛选出符合标准的文献,采用RevMan5.3软件进行Meta分析。结果最终纳入13篇文献,包括1 736例病人,其中观察组875例,对照组861例。术后1个月,观察组左室射血分数(LVEF)高于对照组[WMD=4.33,95%CI(2.98,5.68),P0.000 01],左室舒张末期内径(LVEDD)小于对照组[WMD=-4.20,95%CI(-5.51,-2.90),P0.000 01],主要心血管不良事件(MACE)发生率低于对照组[RR=0.53,95%CI(0.39,0.72),P0.000 1],血小板计数优于对照组[WMD=33.06,95%CI(29.90,36.22),P0.000 01];术后1个月两组呼吸困难发生率[RR=1.60,95%CI(0.83,3.12),P=0.16]、出血发生率[RR=1.34,95%CI(0.82,2.19),P=0.24]比较差异均无统计学意义(P0.05)。结论当前证据表明:替格瑞洛较氯吡格雷联合PCI治疗STEMI的疗效显著,且未增加严重出血事件和不良反应。     

针刺治疗糖尿病周围神经病变疗效的Meta分析及试验序贯分析

目的系统评价针刺治疗糖尿病周围神经病变的疗效。方法计算机检索中国知网(CNKI)、万方(WANFANG),中国生物医学文献数据库(CBM)、维普数据库(VIP)、PubMed、EMBase和Cochrane图书馆,收集针刺治疗对比非针刺治疗糖尿病周围神经病变疗效(神经传导速度,体征及症状积分)的随机对照试验(RCT),对符合纳入标准的临床研究进行资料提取和质量评价后,采用Stata14.0软件进行Meta分析,用TSA0.9软件进行试验序贯分析。结果共纳入16项RCT,共计1 208例患者。Meta分析结果显示,试验组临床疗效[RR=1.14,95%CI(1.03～1.27),P0.000 1],体征积分[WMD=-1.81,95%CI(-1.88～-1.75),P0.000 1],症状积分[WMD=-3.39,95%CI(-3.46～-3.32),P0.000 1],腓总神经运动传导速度[WMD=4.58,95%CI(3.86～5.31),P0.000 1],腓总神经感觉传导速度[WMD=3.47,95%CI(2.99～3.95),P0.000 1],正中神经运动传导速度[WMD=4.56,95%CI(3.97～5.15),P0.000 1],正中神经感觉传导速度[WMD=3.17,95%CI(2.48～3.86),P0.000 1],多伦多临床神经病变评分[WMD=-2.07,95%CI(-2.27～-1.86),P0.000 1],与对照组比较差异均有统计学意义(P0.05)。结论针刺治疗对比非针刺治疗糖尿病周围神经病变的疗效均较好。     

左西孟旦治疗难治性心力衰竭的有效性与安全性的Meta分析

目的:评价左西孟旦治疗难治性心力衰竭(RHF)的效果及安全性。方法:计算机检索PubMed、中国期刊全文数据库、万方全文数据库、中国生物医学文献数据库等有关左孟西旦与米力农治疗RHF效果的随机对照试验RCT,检索时限为建库至2015年1月,在客观评价文献质量后采用RevMan 5.3软件对纳入的试验结果进行Meta分析。结果:共纳入8篇RCT文献,共552例患者。Meta分析结果显示:有效性方面:评估心力衰竭疗效总有效率差异有统计学意义[RR=1.30,95%CI=(1.18,1.44),P0.000 01];治疗前两组左室射血分数(LVEF)差异无统计学意[SMD=0.08,95%CI=(-0.12,0.27),P0.000 01];治疗后与米力农组相比较,左西孟旦组LVEF有显著提高[SMD=0.53,95%CI=(0.35,0.72),P0.000 01]。安全性方面:左西孟旦组和米力农组所致不良反应差异无统计学意义[RR=0.83,95%CI=(0.47,1.44),P=0.50]。结论:左西孟旦治疗RHF的效果优于米力农,能显著提高LVEF,但两者在药物不良反应方面无统计学差异。     

步长脑心通胶囊治疗高脂血症的系统评价

目的系统评价步长脑心通胶囊治疗高脂血症的疗效和安全性。方法计算机检索Cochrane图书馆、PubMed、EMbase、Medline、CNKI、CBM、VIP、万方数据库等数据库,纳入相关随机对照试验(RCT),并进行评价,采用RevMan5.3软件分析数据。结果纳入35篇RCT,共3 855例受试者。相比常规治疗或单独使用西药治疗(对照组),步长脑心通胶囊治疗(试验组)的血脂总疗效高于对照组[RR=1.21, 95%CI(1.15, 1.28),P0.000 01],治疗后总胆固醇(TC)水平低于对照组[WMD=-0.77, 95%CI(-0.91,-0.64),P0.000 01],治疗后三酰甘油(TG)水平低于对照组[WMD=-0.58, 95%CI(-0.68,-0.48),P0.000 01],治疗后高密度脂蛋白(HDL-C)高于对照组[WMD=0.20, 95%CI(0.13, 0.27),P0.000 01],治疗后低密度脂蛋白胆固醇(LDL-C)水平低于对照组[WMD=-0.58, 95%CI(-0.73,-0.43),P0.000 01],各组不良反应发生率差异无统计学意义[RR=0.85, 95%CI(0.58, 1.24),P=0.40]。结论步长脑心通胶囊治疗高脂血症疗效明显,对TC、TG、HDL-C、LDL-C的改善均较有效,不良反应发生率未见与其他药物有明显差异。     

益生菌制剂治疗肝硬化的meta分析

背景:肠道菌群失调在肝硬化及其并发症的发生中起重要作用。近年来益生菌制剂在肝硬化治疗中的应用引起了广泛关注。目的:评价益生菌制剂治疗肝硬化的疗效。方法:检索PubMed、Springer Link、Wiley Online Library、MEDLINE、Web of Science、The Cochrane Library以及CNKI、维普、万方数据库,选取关于益生菌制剂治疗肝硬化的随机对照试验(RCTs),应用RevMan 5.1软件进行meta分析。二分类变量和连续变量分别采用相对危险度(RR)和加权均数差(WMD)或标准化均数差(SMD)进行评估。结果:共27项RCTs满足纳入和排除标准。与对照组相比,益生菌制剂可显著降低肝硬化患者的外周血ALT(WMD=15.08,95%CI:6.67~23.49,P=0.000 4)、AST(WMD=5.24,95%CI:0.75~9.73,P=0.02)水平和血氨(SMD=0.35,95%CI:0.16~0.54,P=0.000 3)、内毒素(SMD=0.75,95%CI:0.55~0.96,P0.000 01)含量,升高血清白蛋白水平(WMD=0.97,95%CI:0.47~1.48,P=0.000 1),缩短数字连接试验(NCT)反应时间(WMD=24.03,95%CI:4.06~44.00,P=0.02),降低肝性脑病(HE)(RR=0.48,95%CI:0.26~0.89,P=0.02)和自发性细菌性腹膜炎(SBP)(RR=0.53,95%CI:0.38~0.74,P=0.000 2)发生率。对肝硬化合并HE的亚组分析显示,益生菌制剂可显著降低HE患者的血氨和内毒素含量。结论:益生菌制剂可明显改善肝硬化患者的临床症状和生化指标,降低HE和SBP的发生风险,对肝硬化合并HE有明显治疗作用。     

Effect of increasing metabolic syndrome score on atherosclerotic risk profile and coronary artery disease angiographic severity

The metabolic syndrome (MS) is a frequent cause of coronary artery disease (CAD), and recently the National Cholesterol Education Program Adult Treatment Panel III suggested its diagnosis in the presence of 3 to 5 quantitatively defined markers. Because the consequences of the MS are likely related to the number and diversity of markers, we studied the relation between the number of markers-the MS score-and the degree of abdominal obesity, risk factor profile, and severity of CAD. One thousand one hundred eight subjects of a mostly white population with symptoms of CAD (793 men and 315 women; 58.1 +/- 9.8 years of age) were divided into 6 groups based on their MS scores. A low high-density lipoprotein cholesterol level was the most frequently observed marker, followed by increased blood pressure, triglycerides, waist circumference, and fasting glucose. As the MS score increased so did abdominal obesity, parameters of "nontraditional" dyslipidemia with surrogate markers of dense low-density lipoprotein and high-density lipoprotein particles, blood pressure, fasting glucose, insulin, and the homeostatic model assessment insulin resistance index. Similarly, an increasing MS score was significantly related to more severe coronary angiographic alterations and higher frequencies of unstable angina, myocardial infarction, percutaneous coronary intervention, and coronary artery bypass grafting. Therefore, the MS score provides a clinically useful index of MS severity and the associated atherosclerotic risk factor profile. It also correlates with the angiographic severity of CAD and its clinical complications.     

Prospective comparison of coronary artery remodeling between acute coronary syndrome and stable angina in single-vessel disease: correlation between C-reactive protein and extent of arterial remodeling

BACKGROUND: Retrospective intravascular ultrasound (IVUS) studies showed that positive remodeling of coronary artery was associated with unstable clinical presentation. However, no prospective IVUS study has been performed to demonstrate such relationship. The relationship between C-reactive protein (CRP) and coronary artery remodeling is unknown. HYPOTHESIS: Positive remodeling might be related with acute coronary syndrome in the prospective IVUS study. C-reactive protein levels might be associated with coronary artery remodeling. METHODS: Preintervention IVUS images were prospectively obtained in 93 patients with single-vessel disease (30 for acute coronary syndrome and 63 for stable angina). Serum sample for CRP measurement was collected 24 h prior to coronary intervention. The remodeling index was defined as a ratio of (lesion/average reference) external elastic membrane area. Positive remodeling was defined as a remodeling index > 1.05 and negative remodeling as a remodeling index < 0.95. RESULTS: The remodeling index was 0.99 +/- 0.13 in acute coronary syndrome versus 0.95 +/- 0.12 in stable angina (p = 0.048). Positive remodeling was associated with acute coronary syndrome (43 vs. 19%), whereas negative remodeling was more frequent in stable angina (49 vs. 33%) (p = 0.047). C-reactive protein levels were significantly higher in acute coronary syndrome than in stable angina (1.4 +/- 2.0 vs. 0.5 +/- 0.6 mg/dl, respectively, p = 0.002). However, there was no significant correlation between CRP levels and remodeling index (r = 0.078, p = 0.475). CONCLUSIONS: Positive remodeling may be related with acute coronary syndrome in the prospective IVUS analysis. C-reactive protein levels may not predict the extent of arterial remodeling.     

非糖尿病急性冠状动脉综合征与急性高血糖的关系

目的:分析冠状动脉的病变程度与应激性高血糖水平的关系.方法:选择126例接受冠状动脉造影的非糖尿病急性冠状动脉综合征住院患者并监测其入院后24 h内血糖水平.根据冠状动脉病变的程度分为单支病变组、双支病变组和多支病变组.结果:多支病变组入院24 h内血糖值显著高于双支病变组[(9.9±1.0 )mmol/L∶(7.6±1.3 )mmol/L]及单支病变组[(9.9±1.0) mmol/L∶(5.9±0.4 )mmol/L],均P＜0.01.双支病变组入院24 h内血糖值同样显著高于单支病变组[(7.6±1.3) mmol/L∶(5.9±0.4 )mmol/L),P＜0.01.结论:在非糖尿病急性冠状动脉综合征患者中,急性期血糖值在一定程度与冠状动脉病变程度相关.     

急性冠脉综合征患者GRACE评分与冠脉病变的相互关系

目的 探讨急性冠脉综合征（ACS）患者全球急性冠状动脉事件注册（GRACE）评分与冠状动脉病变程度的关系,评价GRACE评分对冠状动脉病变预测的价值.方法 收集2008年5月至2010年10月住院的ACS患者共360例,对其进行GRACE评分.以评分差异分组,分为高危组、中危组和低危组,分析不同组别中患者冠状动脉病变的严重程度,以及与GRACE评分的关系.结果 随着GRACE评分分值的增加,ACS患者冠状动脉狭窄支数及狭窄程度呈增加的趋势.结论 GRACE评分对ACS患者冠状动脉病变支数、狭窄严重程度有一定的预测价值.     

超质量和肥胖急性冠状动脉综合征患者超敏C-反应蛋白水平与冠状动脉Gensini积分的关系

目的:分析超质量和肥胖急性冠状动脉综合征(ACS)患者超敏C反应蛋白(hs-CRP)水平与冠状动脉病变复杂程度之间的关系。方法:入选2012年1月至2012年12月,于北京安贞医院行冠状动脉造影并确诊为ACS的患者304例,根据体质量指数(BMI)分为肥胖ACS组[BMI≥27(kg/m2)]84例、超质量ACS组[24≤BMI27/(kg/m2)]133例,正常体质量ACS对照组[18.5≤BMI24/(kg/m2)]87例。根据造影结果,按狭窄病变血管数分为单支病变及多支病变(2支病变以上);采用Gensini积分方法对冠状动脉狭窄程度进行定量评分,检测hs-CRP水平,分析hs-CRP与Gensini积分之间关系。结果:超质量和肥胖ACS患者hs-CRP水平显著高于对照组,超质量和肥胖ACS患者冠状动脉多支血管病变者较多,发生ACS的年龄较早;超质量和肥胖ACS患者hs-CRP水平与Gensini积分之间成显著正相关。结论:与正常体质量ACS患者相比,超质量及肥胖ACS患者的hs-CRP水平较高;血清hs-CRP水平与Gensini积分正相关,hs-CRP对于预测超质量和肥胖ACS患者冠状动脉病变复杂程度有一定价值,超质量及肥胖者应加强冠心病的一级预防。     

Stent implantation for acute left main coronary artery occlusion in an HIV-infected patient on protease inhibitors

A previously unreported complication, acute left main coronary artery occlusion with anterior myocardial infarction, in a patient at low coronary risk under HIV protease inhibitors, is described. Severe premature coronary artery disease has been reported in young men receiving HIV protease inhibitors, usually associated with hypertriglyceridemia, hypercholesterolemia, glucose intolerance and lipodystrophy syndrome. Percutaneous transluminal coronary angioplasty and stent implantation were successfully performed.     

C-reactive protein concentrations are related to insulin resistance and metabolic syndrome as defined by the ATP III report

BACKGROUND: C-reactive protein (CRP), very sensitive acute phase reactant, is an important marker of coronary artery disease. However, the relationship between insulin resistance and CRP has not been thoroughly studied. We observed the association between CRP, insulin resistance and metabolic syndrome as defined by the ATP III report, and thus identified the role of CRP in the relation to insulin resistance. METHODS: Seven hundred and sixty-seven subjects (436 men, 331 women) who underwent a medical check-up at health promotion center in a University Hospital during March 2002, aged 20-84 years, were included in this study. The components of metabolic syndrome as defined by the ATP III report and high sensitivity CRP levels were analyzed, and Homeostasis model assessment index (HOMA) and quantitative insulin sensitivity check index (QUICKI) were calculated. RESULTS: The mean concentrations of CRP in subjects according to the presence of 0, 1, 2, 3, 4, or 5 components of metabolic syndrome as defined by ATP III were 0.64, 0.95, 1.14, 1.19, 2.40, and 2.53 mg/l, respectively. The mean concentrations of CRP were significantly higher in subjects with a high insulin resistance (higher HOMA index and lower QUICKI) than in those with a low insulin resistance. Significant positive correlations were identified between CRP and BMI, waist circumference, triglyceride, blood pressure, glucose and HOMA index. A significant negative correlation was found between CRP and HDL cholesterol or QUICKI. CONCLUSION: These results suggest that metabolic syndrome and insulin resistance are associated with systemic inflammatory response, which plays an important pathogenic role in atherosclerosis.     

ABI、CAVI与冠状动脉病变关系临床研究

目的观察冠状动脉粥样硬化性心脏病（冠心病）患者踝臂指数（ABI）、心踝血管指数（CAVI）水平,并探讨其与冠状动脉病变之间关系。方法选取行冠状动脉造影的95例患者,其中35例为急性冠脉综合征（ACS）患者,30例为慢性稳定性冠心病（SCHD）患者,另30例为冠状动脉造影正常患者（对照组）。各组均检测ABI、CAVI指标,分析其与冠状动脉病变关系。结果 ACS组ABI水平明显低于对照组及SCHD组,差异有显著统计学意义（P均〈0.01）。ACS组与SCHD组CAVI水平明显高于对照组（P〈0.01）,且ACS组CAVI水平高于SCHD组,差异有显著统计学意义（P〈0.01）。结论冠心病尤其ACS患者动脉血管僵硬程度更高。     

急性冠状动脉综合征患者血清脂联素和踝臂指数的变化及其相关性的研究

目的观察急性冠状动脉综合征(ACS)患者血清脂联素(APN)水平和踝臂指数(ABI)值的变化及其与ACS的相关性,评估APN和ABI在ACS发生中的价值。方法依据临床表现及冠状动脉(冠脉)造影等检查,将69例冠心病患者分为ACS组(44例)与稳定型心绞痛(SAP)组(25例),其中按狭窄所累及的血管病变支数分为:单支病变组(25例),双支病变组(20例),三支病变组(24例);根据Gensini积分分为:1～30分组(48例)、≥30分组(21例);选取冠脉造影阴性者(22例)为对照(NC)组。比较各组间APN、ABI的差异。结果 (1)APN水平、ABI值ACS组均明显低于SAP组和NC组(均为P<0.05)。(2)APN水平、ABI值随着冠脉病变支数的增加均逐渐下降,相关分析提示APN、ABI值均与病变支数呈负相关(分别为r=-0.733,P<0.01;r=-0.632,P<0.01)。(3)APN水平、ABI值随着冠脉Gensini积分的增加均逐渐下降,相关分析提示APN、ABI值与Gensini积分均呈负相关(分别为r=-0.640,P<0.01;r=-0.697,P<0.01)。(4)ACS患者血清APN与ABI值呈正相关(r=0.622,P<0.01)。结论血清APN水平、ABI值随着冠脉病变程度的加重和病变范围的扩大而降低,APN和ABI值越低,冠脉病变程度可能越严重,病变范围可能越广。     

急性冠脉综合征患者血糖变异性与冠脉病变程度相关性研究

目的比较合并糖尿病的急性冠状动脉综合征（ACS）患者和无糖尿病ACS患者临床特点的差异，并研究ACS患者住院期间血糖变异性与冠脉狭窄程度相关性。方法记录878例ACS患者基线时各指标、临床特点、住院期间不良事件发生情况以及住院期间所有测得的血糖结果，计算每例患者住院期间血糖的平均值、变异系数。（1）将878例ACS患者按照入院前有无糖尿病史分为合并糖尿病的ACS组和无糖尿病ACS组，对记录的主要资料进行回顾性分析，比较各组临床特点；（2）将所有ACS患者分别按照其住院期间血糖变异性或住院期间平均血糖水平各分4组（四分位法），比较各组冠脉病变特点；（3）多元逐步回归分析冠脉病变严重程度（指标为gensini狭窄分数）的相关因素。结果（1）合并糖尿病的ACS患者较之无糖尿病者年龄更大，体重指数更高，多为女性，吸烟、高血压、高胆固醇血症、高甘油三酯血症所占比例更高，高密度脂蛋白-胆固醇平均水平更低、纤维蛋白原平均水平更高，更少接受经皮冠状动脉介入治疗或冠状动脉旁路移植术等积极心脏治疗措施，住院期间死亡率及其他住院期间不良事件发生率、冠脉狭窄分数更高且上述差异均有显著性；尿酸平均水平、低密度脂蛋白-胆固醇平均水平低于无糖尿病者，但无显著性差异。（2）将所有ACS患者分别按照其住院期间血糖变异性分为4组（四分位法），发现随血糖变异性增大，冠脉病变支数增多、冠脉狭窄分数升高。按照住院期间血糖平均水平分组时其结果也相同。（3）ACS患者住院期间血糖变异性与冠脉狭窄程度独立相关。结论阳性糖尿病史、住院期间平均血糖水平高、血糖变异性大均提示冠状动脉病变程度重、近期预后不良。应临床重视ACS患者血糖的监测并加强对ACS患者的血糖控制。